Cutiss AG has raised fresh capital from a still ongoing Series B financing round, as detailed in a press release. The investors included the Gisev Family Office and the Wyss Foundation, in addition to new and existing private investors, among others. Overall, the start-up has so far raised a total of 18.7 million Swiss francs, according to information in the press release.
Cutiss is a spin-off of the University of Zurich (UZH) that develops personalized, permanent skin grafts to treat skin defects, including those as a result of burn injuries. For this, skin tissue is taken from the patient, which is then grown and stretched to produce larger skin grafts and reduce the formation of scarring. To this end, Cutiss uses its proprietary denovoSkin technology.
Cutiss is now planning to use the fresh capital to advance clinical trials. Moreover, the company is looking to scale up manufacturing at Bio-Technopark Schlieren-Zurich. Cutiss is also working on plans to produce a functioning prototype machine for the automated production of large quantities of skin. By 2022, the company is also aiming to have fulfilled the requirements for market authorization in Switzerland and the European Union.
